Biomarkers and immunotherapy: where are we?

Auteurs : Langouo Fontsa M, Padonou F, Willard-Gallo K
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 579-586

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.

Auteurs : Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B
Année : 2022
Journal : Cancers (Basel)
Volume : 14

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Auteurs : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Année : 2022
Journal : Diagnostics (Basel)
Volume : 12

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.

Auteurs : Garaud S, Dieu-Nosjean MC, Willard-Gallo K
Année : 2022
Journal : Nat Commun
Volume : 13
Pages : 2259

Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.

Auteurs : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.

Auteurs : Langouo Fontsa M, Aiello MM, Migliori E, Scartozzi M, Lambertini M, Willard-Gallo K, Solinas C
Année : 2022
Journal : Target Oncol
Volume : 17
Pages : 497-505

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Année : 2022
Journal : J Cancer Res Clin Oncol
Pages : 1-6

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.

Auteurs : van de Stolpe A, Verhaegh W, Blay JY, Ma CX, Pauwels P, Pegram M, Prenen H, De Ruysscher D, Saba NF, Slovin SF, Willard-Gallo K, Husain H
Année : 2021
Journal : Front Genet
Volume : 11
Pages : 598118

Downregulation of the FTO m⁶A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.

Auteurs : Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F
Année : 2021
Journal : Nat Cancer
Volume : 2
Pages : 611-628

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.

Auteurs : Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C
Année : 2021
Journal : Mol Diagn Ther
Volume : 25
Pages : 409-424

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Auteurs : El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S
Année : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 150

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.

Auteurs : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S
Année : 2021
Journal : Front Mol Biosci
Volume : 8
Pages : 673042

A review of immune checkpoint blockade in breast cancer.

Auteurs : Pellegrino B, Tommasi C, Cursio OE, Musolino A, Migliori E, De Silva P, Senevirathne TH, Schena M, Scartozzi M, Farci D, Willard-Gallo K, Solinas C
Année : 2021
Journal : Semin Oncol
Volume : 48
Pages : 208-225

B cells and cancer.

Auteurs : Engelhard V, Conejo-Garcia JR, Ahmed R, Nelson BH, Willard-Gallo K, Bruno TC, Fridman WH
Année : 2021
Journal : Cancer Cell
Volume : 39
Pages : 1293-1296

Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity.

Auteurs : Noël G, Fontsa ML, Garaud S, De Silva P, de Wind A, Van den Eynden GG, Salgado R, Boisson A, Locy H, Thomas N, Solinas C, Migliori E, Naveaux C, Duvillier H, Lucas S, Craciun L, Thielemans K, Larsimont D, Willard-Gallo K
Année : 2021
Journal : J Clin Invest
Volume : 131

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis.

Auteurs : Caparica R, Bruzzone M, Agostinetto E, Franzoi MA, Ceppi M, Radosevic-Robin N, Penault-Llorca F, Willard-Gallo K, Loi S, Salgado R, de Azambuja E
Année : 2021
Journal : Breast
Volume : 59
Pages : 183-192

Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?

Auteurs : De Silva P, Aiello M, Gu-Trantien C, Migliori E, Willard-Gallo K, Solinas C
Année : 2021
Journal : Int J Cancer
Volume : 149
Pages : 31-41

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Auteurs : Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Lænkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudecek J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R
Année : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 17

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

Auteurs : Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart-Gebhart M, Sotiriou C, González-Suárez E
Année : 2020
Journal : Nat Commun
Volume : 11
Pages : 6335

Radiomics and radi-…omics" in cancer immunotherapy: a guide for clinicians."

Auteurs : Porcu M, Solinas C, Mannelli L, Micheletti G, Lambertini M, Willard-Gallo K, Neri E, Flanders AE, Saba L
Année : 2020
Journal : Crit Rev Oncol Hematol
Volume : 154
Pages : 103068